Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 101

1.

Circulating Tumor Cells are an Independent Predictor of Shorter Survival in Patients Undergoing Resection for Pancreatic and Periampullary Adenocarcinoma.

Hugenschmidt H, Labori KJ, Brunborg C, Verbeke CS, Seeberg LT, Schirmer CB, Renolen A, Borgen EF, Naume B, Wiedswang G.

Ann Surg. 2018 Sep 13. doi: 10.1097/SLA.0000000000003035. [Epub ahead of print]

PMID:
30216219
2.

Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis.

Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, Lucci A, Naume B, Horiguchi J, Gisbert-Criado R, Sleijfer S, Toi M, Garcia-Saenz JA, Hartkopf A, Generali D, Rothé F, Smerage J, Muinelo-Romay L, Stebbing J, Viens P, Magbanua MJM, Hall CS, Engebraaten O, Takata D, Vidal-Martínez J, Onstenk W, Fujisawa N, Diaz-Rubio E, Taran FA, Cappelletti MR, Ignatiadis M, Proudhon C, Wolf DM, Bauldry JB, Borgen E, Nagaoka R, Carañana V, Kraan J, Maestro M, Brucker SY, Weber K, Reyal F, Amara D, Karhade MG, Mathiesen RR, Tokiniwa H, Llombart-Cussac A, Meddis A, Blanche P, d'Hollander K, Cottu P, Park JW, Loibl S, Latouche A, Pierga JY, Pantel K.

J Natl Cancer Inst. 2018 Jun 1;110(6):560-567. doi: 10.1093/jnci/djy018.

PMID:
29659933
3.

The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTTO.

Di Cosimo S, Campbell C, Azim HA Jr, Galli G, Bregni G, Curigliano G, Criscitiello C, Izquierdo M, de la Pena L, Fumagalli D, Fein L, Vinholes J, Ng WMJ, Colleoni M, Ferro A, Naume BJ, Patel A, Huober J, Piccart-Gebhart MJ, Baselga J, de Azambuja E.

Eur J Cancer. 2018 Jan;89:42-48. doi: 10.1016/j.ejca.2017.10.036. Epub 2017 Dec 8.

PMID:
29227816
4.

Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients.

Helland T, Henne N, Bifulco E, Naume B, Borgen E, Kristensen VN, Kvaløy JT, Lash TL, Alnæs GIG, van Schaik RH, Janssen EAM, Hustad S, Lien EA, Mellgren G, Søiland H.

Breast Cancer Res. 2017 Nov 28;19(1):125. doi: 10.1186/s13058-017-0916-4.

5.

Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up.

Ohnstad HO, Borgen E, Falk RS, Lien TG, Aaserud M, Sveli MAT, Kyte JA, Kristensen VN, Geitvik GA, Schlichting E, Wist EA, Sørlie T, Russnes HG, Naume B.

Breast Cancer Res. 2017 Nov 14;19(1):120. doi: 10.1186/s13058-017-0911-9.

6.

DNA methylation at enhancers identifies distinct breast cancer lineages.

Fleischer T, Tekpli X, Mathelier A, Wang S, Nebdal D, Dhakal HP, Sahlberg KK, Schlichting E; Oslo Breast Cancer Research Consortium (OSBREAC), Børresen-Dale AL, Borgen E, Naume B, Eskeland R, Frigessi A, Tost J, Hurtado A, Kristensen VN.

Nat Commun. 2017 Nov 9;8(1):1379. doi: 10.1038/s41467-017-00510-x.

7.

Data-driven analysis of immune infiltrate in a large cohort of breast cancer and its association with disease progression, ER activity, and genomic complexity.

Dannenfelser R, Nome M, Tahiri A, Ursini-Siegel J, Vollan HKM, Haakensen VD, Helland Å, Naume B, Caldas C, Børresen-Dale AL, Kristensen VN, Troyanskaya OG.

Oncotarget. 2017 Jul 7;8(34):57121-57133. doi: 10.18632/oncotarget.19078. eCollection 2017 Aug 22.

8.

Widespread alternative exon usage in clinically distinct subtypes of Invasive Ductal Carcinoma.

Bjørklund SS, Panda A, Kumar S, Seiler M, Robinson D, Gheeya J, Yao M, Alnæs GIG, Toppmeyer D, Riis M, Naume B, Børresen-Dale AL, Kristensen VN, Ganesan S, Bhanot G.

Sci Rep. 2017 Jul 17;7(1):5568. doi: 10.1038/s41598-017-05537-0.

9.

Specific antibodies and sensitive immunoassays for the human epidermal growth factor receptors (HER2, HER3, and HER4).

Broughton MN, Westgaard A, Paus E, Øijordsbakken M, Henanger KJ, Naume B, Bjøro T.

Tumour Biol. 2017 Jun;39(6):1010428317707436. doi: 10.1177/1010428317707436.

PMID:
28653892
10.

The Longitudinal Transcriptional Response to Neoadjuvant Chemotherapy with and without Bevacizumab in Breast Cancer.

Silwal-Pandit L, Nord S, von der Lippe Gythfeldt H, Møller EK, Fleischer T, Rødland E, Krohn M, Borgen E, Garred Ø, Olsen T, Vu P, Skjerven H, Fangberget A, Holmen MM, Schlitchting E, Wille E, Nordberg Stokke M, Moen Vollan HK, Kristensen V, Langerød A, Lundgren S, Wist E, Naume B, Lingjærde OC, Børresen-Dale AL, Engebraaten O.

Clin Cancer Res. 2017 Aug 15;23(16):4662-4670. doi: 10.1158/1078-0432.CCR-17-0160. Epub 2017 May 9.

11.

Regional Nodal Irradiation After Breast Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTTO Trial.

Gingras I, Holmes E, De Azambuja E, Nguyen DH, Izquierdo M, Anne Zujewski J, Inbar M, Naume B, Tomasello G, Gralow JR, Wolff AC, Harris L, Gnant M, Moreno-Aspitia A, Piccart MJ, Azim HA Jr.

J Natl Cancer Inst. 2017 Aug 1;109(8). doi: 10.1093/jnci/djw331.

PMID:
28376188
12.

Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome.

Aure MR, Vitelli V, Jernström S, Kumar S, Krohn M, Due EU, Haukaas TH, Leivonen SK, Vollan HK, Lüders T, Rødland E, Vaske CJ, Zhao W, Møller EK, Nord S, Giskeødegård GF, Bathen TF, Caldas C, Tramm T, Alsner J, Overgaard J, Geisler J, Bukholm IR, Naume B, Schlichting E, Sauer T, Mills GB, Kåresen R, Mælandsmo GM, Lingjærde OC, Frigessi A, Kristensen VN, Børresen-Dale AL, Sahlberg KK; OSBREAC.

Breast Cancer Res. 2017 Mar 29;19(1):44. doi: 10.1186/s13058-017-0812-y.

13.

Survival Impact of Primary Tumor Lymph Node Status and Circulating Tumor Cells in Patients with Colorectal Liver Metastases.

Seeberg LT, Brunborg C, Waage A, Hugenschmidt H, Renolen A, Stav I, Bjørnbeth BA, Borgen E, Naume B, Brudvik KW, Wiedswang G.

Ann Surg Oncol. 2017 Aug;24(8):2113-2121. doi: 10.1245/s10434-017-5818-2. Epub 2017 Mar 3.

14.

Prognostic significance of S100A4-expression and subcellular localization in early-stage breast cancer.

Egeland EV, Boye K, Park D, Synnestvedt M, Sauer T; Oslo Breast Cancer Consortium (OSBREAC), Naume B, Borgen E, Mælandsmo GM.

Breast Cancer Res Treat. 2017 Feb;162(1):127-137. doi: 10.1007/s10549-016-4096-1. Epub 2017 Jan 5.

PMID:
28058579
15.

Fatigue During and After Breast Cancer Therapy-A Prospective Study.

Reinertsen KV, Engebraaten O, Loge JH, Cvancarova M, Naume B, Wist E, Edvardsen H, Wille E, Bjøro T, Kiserud CE.

J Pain Symptom Manage. 2017 Mar;53(3):551-560. doi: 10.1016/j.jpainsymman.2016.09.011. Epub 2016 Dec 29.

PMID:
28042070
16.

Tracing the origin of disseminated tumor cells in breast cancer using single-cell sequencing.

Demeulemeester J, Kumar P, Møller EK, Nord S, Wedge DC, Peterson A, Mathiesen RR, Fjelldal R, Zamani Esteki M, Theunis K, Fernandez Gallardo E, Grundstad AJ, Borgen E, Baumbusch LO, Børresen-Dale AL, White KP, Kristensen VN, Van Loo P, Voet T, Naume B.

Genome Biol. 2016 Dec 9;17(1):250.

17.

DNA methylation signature (SAM40) identifies subgroups of the Luminal A breast cancer samples with distinct survival.

Fleischer T, Klajic J, Aure MR, Louhimo R, Pladsen AV, Ottestad L, Touleimat N, Laakso M, Halvorsen AR, Grenaker Alnæs GI, Riis ML, Helland Å, Hautaniemi S, Lønning PE, Naume B, Børresen-Dale AL, Tost J, Kristensen VN.

Oncotarget. 2017 Jan 3;8(1):1074-1082. doi: 10.18632/oncotarget.13718.

18.

Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET).

Jerusalem G, Mariani G, Ciruelos EM, Martin M, Tjan-Heijnen VC, Neven P, Gavila JG, Michelotti A, Montemurro F, Generali D, Simoncini E, Lang I, Mardiak J, Naume B, Camozzi M, Lorizzo K, Bianchetti S, Conte P.

Ann Oncol. 2016 Sep;27(9):1719-25. doi: 10.1093/annonc/mdw249. Epub 2016 Jun 29.

PMID:
27358383
19.

The Sub-Cellular Localization of WRAP53 Has Prognostic Impact in Breast Cancer.

Silwal-Pandit L, Russnes H, Borgen E, Skarpeteig V, Moen Vollan HK, Schlichting E, Kåresen R, Naume B, Børresen-Dale AL, Farnebo M, Langerød A.

PLoS One. 2015 Oct 13;10(10):e0139965. doi: 10.1371/journal.pone.0139965. eCollection 2015.

20.

Serum N-glycan analysis in breast cancer patients--Relation to tumour biology and clinical outcome.

Haakensen VD, Steinfeld I, Saldova R, Shehni AA, Kifer I, Naume B, Rudd PM, Børresen-Dale AL, Yakhini Z.

Mol Oncol. 2016 Jan;10(1):59-72. doi: 10.1016/j.molonc.2015.08.002. Epub 2015 Aug 19.

21.

Expression of an estrogen-regulated variant transcript of the peroxisomal branched chain fatty acid oxidase ACOX2 in breast carcinomas.

Bjørklund SS, Kristensen VN, Seiler M, Kumar S, Alnæs GI, Ming Y, Kerrigan J, Naume B, Sachidanandam R, Bhanot G, Børresen-Dale AL, Ganesan S.

BMC Cancer. 2015 Jul 17;15:524. doi: 10.1186/s12885-015-1510-8.

22.

Detection of Circulating Tumor Cells at Surgery and at Follow-Up Assessment to Predict Survival After Two-Stage Liver Resection of Colorectal Liver Metastases.

Brudvik KW, Seeberg LT, Hugenschmidt H, Renolen A, Schirmer CB, Brunborg C, Bjørnbeth BA, Borgen E, Naume B, Waage A, Wiedswang G.

Ann Surg Oncol. 2015 Nov;22(12):4029-37. doi: 10.1245/s10434-015-4482-7. Epub 2015 Mar 24.

PMID:
25801354
23.

A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients.

Kleivi Sahlberg K, Bottai G, Naume B, Burwinkel B, Calin GA, Børresen-Dale AL, Santarpia L.

Clin Cancer Res. 2015 Mar 1;21(5):1207-14. doi: 10.1158/1078-0432.CCR-14-2011. Epub 2014 Dec 29.

24.

Quantitative multigene FISH on breast carcinomas identifies der(1;16)(q10;p10) as an early event in luminal A tumors.

Rye IH, Lundin P, Månér S, Fjelldal R, Naume B, Wigler M, Hicks J, Børresen-Dale AL, Zetterberg A, Russnes HG.

Genes Chromosomes Cancer. 2015 Apr;54(4):235-48. doi: 10.1002/gcc.22237. Epub 2014 Dec 26.

25.

Clinical outcome with correlation to disseminated tumor cell (DTC) status after DTC-guided secondary adjuvant treatment with docetaxel in early breast cancer.

Naume B, Synnestvedt M, Falk RS, Wiedswang G, Weyde K, Risberg T, Kersten C, Mjaaland I, Vindi L, Sommer HH, Sætersdal AB, Rypdal MC, Bendigtsen Schirmer C, Wist EA, Borgen E.

J Clin Oncol. 2014 Dec 1;32(34):3848-57. doi: 10.1200/JCO.2014.56.9327. Epub 2014 Nov 3.

PMID:
25366688
26.

Long non-coding RNAs differentially expressed between normal versus primary breast tumor tissues disclose converse changes to breast cancer-related protein-coding genes.

Reiche K, Kasack K, Schreiber S, Lüders T, Due EU, Naume B, Riis M, Kristensen VN, Horn F, Børresen-Dale AL, Hackermüller J, Baumbusch LO.

PLoS One. 2014 Sep 29;9(9):e106076. doi: 10.1371/journal.pone.0106076. eCollection 2014.

27.

Genome-wide DNA methylation profiles in progression to in situ and invasive carcinoma of the breast with impact on gene transcription and prognosis.

Fleischer T, Frigessi A, Johnson KC, Edvardsen H, Touleimat N, Klajic J, Riis ML, Haakensen VD, Wärnberg F, Naume B, Helland A, Børresen-Dale AL, Tost J, Christensen BC, Kristensen VN.

Genome Biol. 2014;15(8):435. doi: 10.1186/PREACCEPT-2333349012841587. Epub 2014 Aug 22.

28.

Comparison of molecular and immunocytochemical methods for detection of disseminated tumor cells in bone marrow from early breast cancer patients.

Gilje B, Nordgård O, Tjensvoll K, Borgen E, Synnestvedt M, Smaaland R, Naume B.

BMC Cancer. 2014 Jul 15;14:514. doi: 10.1186/1471-2407-14-514.

29.

International study on inter-reader variability for circulating tumor cells in breast cancer.

Ignatiadis M, Riethdorf S, Bidard FC, Vaucher I, Khazour M, Rothé F, Metallo J, Rouas G, Payne RE, Coombes R, Teufel I, Andergassen U, Apostolaki S, Politaki E, Mavroudis D, Bessi S, Pestrin M, Di Leo A, Campion M, Reinholz M, Perez E, Piccart M, Borgen E, Naume B, Jimenez J, Aura C, Zorzino L, Cassatella M, Sandri M, Mostert B, Sleijfer S, Kraan J, Janni W, Fehm T, Rack B, Terstappen L, Repollet M, Pierga JY, Miller C, Sotiriou C, Michiels S, Pantel K.

Breast Cancer Res. 2014 Apr 23;16(2):R43. doi: 10.1186/bcr3647.

30.

A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease.

Coleman R, Aksnes AK, Naume B, Garcia C, Jerusalem G, Piccart M, Vobecky N, Thuresson M, Flamen P.

Breast Cancer Res Treat. 2014 Jun;145(2):411-8. doi: 10.1007/s10549-014-2939-1. Epub 2014 Apr 13.

31.

Circulating tumor cells in patients with colorectal liver metastasis predict impaired survival.

Seeberg LT, Waage A, Brunborg C, Hugenschmidt H, Renolen A, Stav I, Bjørnbeth BA, Brudvik KW, Borgen EF, Naume B, Wiedswang G.

Ann Surg. 2015 Jan;261(1):164-71. doi: 10.1097/SLA.0000000000000580.

PMID:
24509211
32.

Next-generation sequencing of disseminated tumor cells.

Møller EK, Kumar P, Voet T, Peterson A, Van Loo P, Mathiesen RR, Fjelldal R, Grundstad J, Borgen E, Baumbusch LO, Naume B, Børresen-Dale AL, White KP, Nord S, Kristensen VN.

Front Oncol. 2013 Dec 31;3:320. doi: 10.3389/fonc.2013.00320. eCollection 2013.

33.

Integrated analysis of high-resolution DNA methylation profiles, gene expression, germline genotypes and clinical end points in breast cancer patients.

Fleischer T, Edvardsen H, Solvang HK, Daviaud C, Naume B, Børresen-Dale AL, Kristensen VN, Tost J.

Int J Cancer. 2014 Jun 1;134(11):2615-25. doi: 10.1002/ijc.28606. Epub 2014 Jan 6.

34.

The clinical impact of mean vessel size and solidity in breast carcinoma patients.

Mikalsen LT, Dhakal HP, Bruland ØS, Naume B, Borgen E, Nesland JM, Olsen DR.

PLoS One. 2013 Oct 11;8(10):e75954. doi: 10.1371/journal.pone.0075954. eCollection 2013.

35.

Disseminated tumour cells in the bone marrow in early breast cancer: morphological categories of immunocytochemically positive cells have different impact on clinical outcome.

Synnestvedt M, Borgen E, Schlichting E, Schirmer CB, Renolen A, Giercksky KE, Nesland JM, Naume B.

Breast Cancer Res Treat. 2013 Apr;138(2):485-97. doi: 10.1007/s10549-013-2439-8. Epub 2013 Mar 3.

PMID:
23456230
36.

Identifying in-trans process associated genes in breast cancer by integrated analysis of copy number and expression data.

Aure MR, Steinfeld I, Baumbusch LO, Liestøl K, Lipson D, Nyberg S, Naume B, Sahlberg KK, Kristensen VN, Børresen-Dale AL, Lingjærde OC, Yakhini Z.

PLoS One. 2013;8(1):e53014. doi: 10.1371/journal.pone.0053014. Epub 2013 Jan 30.

37.

Disseminated tumor cells as selection marker and monitoring tool for secondary adjuvant treatment in early breast cancer. Descriptive results from an intervention study.

Synnestvedt M, Borgen E, Wist E, Wiedswang G, Weyde K, Risberg T, Kersten C, Mjaaland I, Vindi L, Schirmer C, Nesland JM, Naume B.

BMC Cancer. 2012 Dec 22;12:616. doi: 10.1186/1471-2407-12-616.

38.

Expression of cyclooxygenase-2 in invasive breast carcinomas and its prognostic impact.

Dhakal HP, Naume B, Synnestvedt M, Borgen E, Kaaresen R, Schlichting E, Wiedswang G, Bassarova A, Holm R, Giercksky KE, Nesland JM.

Histol Histopathol. 2012 Oct;27(10):1315-25. doi: 10.14670/HH-27.1315.

PMID:
22936450
39.

Combined analysis of vascular invasion, grade, HER2 and Ki67 expression identifies early breast cancer patients with questionable benefit of systemic adjuvant therapy.

Synnestvedt M, Borgen E, Russnes HG, Kumar NT, Schlichting E, Giercksky KE, Kåresen R, Nesland JM, Naume B.

Acta Oncol. 2013 Jan;52(1):91-101. doi: 10.3109/0284186X.2012.713508. Epub 2012 Aug 30.

PMID:
22934555
40.

Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival.

Mathiesen RR, Borgen E, Renolen A, Løkkevik E, Nesland JM, Anker G, Ostenstad B, Lundgren S, Risberg T, Mjaaland I, Kvalheim G, Lønning PE, Naume B.

Breast Cancer Res. 2012 Aug 14;14(4):R117. doi: 10.1186/bcr3242.

41.

Expression of vascular endothelial growth factor and vascular endothelial growth factor receptors 1 and 2 in invasive breast carcinoma: prognostic significance and relationship with markers for aggressiveness.

Dhakal HP, Naume B, Synnestvedt M, Borgen E, Kaaresen R, Schlichting E, Wiedswang G, Bassarova A, Holm R, Giercksky KE, Nesland JM.

Histopathology. 2012 Sep;61(3):350-64. doi: 10.1111/j.1365-2559.2012.04223.x. Epub 2012 Jun 13.

PMID:
22690749
42.

Gefitinib in Combination with Weekly Docetaxel in Patients with Metastatic Breast Cancer Caused Unexpected Toxicity: Results from a Randomized Phase II Clinical Trial.

Engebraaten O, Edvardsen H, Løkkevik E, Naume B, Kristensen V, Ottestad L, Natarajan V.

ISRN Oncol. 2012;2012:176789. doi: 10.5402/2012/176789. Epub 2012 May 14.

43.

A prognostic gene expression profile that predicts circulating tumor cell presence in breast cancer patients.

Molloy TJ, Roepman P, Naume B, van't Veer LJ.

PLoS One. 2012;7(2):e32426. doi: 10.1371/journal.pone.0032426. Epub 2012 Feb 23.

44.

High-resolution analyses of copy number changes in disseminated tumor cells of patients with breast cancer.

Mathiesen RR, Fjelldal R, Liestøl K, Due EU, Geigl JB, Riethdorf S, Borgen E, Rye IH, Schneider IJ, Obenauf AC, Mauermann O, Nilsen G, Christian Lingjaerde O, Børresen-Dale AL, Pantel K, Speicher MR, Naume B, Baumbusch LO.

Int J Cancer. 2012 Aug 15;131(4):E405-15. doi: 10.1002/ijc.26444. Epub 2011 Nov 9.

45.

Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling.

Kristensen VN, Vaske CJ, Ursini-Siegel J, Van Loo P, Nordgard SH, Sachidanandam R, Sørlie T, Wärnberg F, Haakensen VD, Helland Å, Naume B, Perou CM, Haussler D, Troyanskaya OG, Børresen-Dale AL.

Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2802-7. doi: 10.1073/pnas.1108781108. Epub 2011 Sep 9.

46.

The prognostic significance of tumour cell detection in the peripheral blood versus the bone marrow in 733 early-stage breast cancer patients.

Molloy TJ, Bosma AJ, Baumbusch LO, Synnestvedt M, Borgen E, Russnes HG, Schlichting E, van't Veer LJ, Naume B.

Breast Cancer Res. 2011 Jun 14;13(3):R61. doi: 10.1186/bcr2898.

47.

Combining gene signatures improves prediction of breast cancer survival.

Zhao X, Rødland EA, Sørlie T, Naume B, Langerød A, Frigessi A, Kristensen VN, Børresen-Dale AL, Lingjærde OC.

PLoS One. 2011 Mar 10;6(3):e17845. doi: 10.1371/journal.pone.0017845.

48.

Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse--a European pooled analysis.

Janni W, Vogl FD, Wiedswang G, Synnestvedt M, Fehm T, Jückstock J, Borgen E, Rack B, Braun S, Sommer H, Solomayer E, Pantel K, Nesland J, Friese K, Naume B.

Clin Cancer Res. 2011 May 1;17(9):2967-76. doi: 10.1158/1078-0432.CCR-10-2515. Epub 2011 Mar 17.

49.

miRNA-mRNA integrated analysis reveals roles for miRNAs in primary breast tumors.

Enerly E, Steinfeld I, Kleivi K, Leivonen SK, Aure MR, Russnes HG, Rønneberg JA, Johnsen H, Navon R, Rødland E, Mäkelä R, Naume B, Perälä M, Kallioniemi O, Kristensen VN, Yakhini Z, Børresen-Dale AL.

PLoS One. 2011 Feb 22;6(2):e16915. doi: 10.1371/journal.pone.0016915.

50.

Methylation profiling with a panel of cancer related genes: association with estrogen receptor, TP53 mutation status and expression subtypes in sporadic breast cancer.

Rønneberg JA, Fleischer T, Solvang HK, Nordgard SH, Edvardsen H, Potapenko I, Nebdal D, Daviaud C, Gut I, Bukholm I, Naume B, Børresen-Dale AL, Tost J, Kristensen V.

Mol Oncol. 2011 Feb;5(1):61-76. doi: 10.1016/j.molonc.2010.11.004. Epub 2010 Nov 25.

Supplemental Content

Support Center